The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours.
Rokaya El AnsariMadeleine L CrazeIslam MiligyMaria Diez-RodriguezChristopher C NolanIan O EllisEmad A RakhaAndrew R GreenPublished in: Breast cancer research : BCR (2018)
SLC7A5 appears to play a role in the aggressive highly proliferative ER+ subtype driven by MYC and could act as a potential therapeutic target. Functional assessment is necessary to reveal the specific role played by this transporter in the ER+ highly proliferative subclass and HER2+ subclass of BC.